Clinical Trials · NCT04989946
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
- Phase
- Phase 1/Phase 2
- Recruitment status
- Recruiting
- Sponsor
- University of Wisconsin, Madison
- Enrollment
- 60
- Start date
- Dec 2021
- Locations
- 1 site, United States
- Primary endpoint
- Pathological Complete Response Rate (pCR)